Evidence map›Paper›PMID 31811481›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020

Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.

Emily A Rosenthal, Pei-Shu Ho, Galen O Joe, Sandra A Mitchell, Susan Booher, Steven Z Pavletic, Kristin Baird, Edward W Cowen, Leora E Comis

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00702689 (A Phase II Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00702689 phase2completednot on this map

A Phase II Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2008 to 2020Enrolled20ConditionsSclerotic Graft Versus Host Disease, Imatinib MesylateArmsGleevec, STI571(Imatinib Mesylate)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Emily A RosenthalRehabilitation Medicine Department, Clinical Center, National Institutes of Health, MSC 1604, 10 Center Drive, Bethesda, MD, 20892, USA.
Pei-Shu HoRehabilitation Medicine Department, Clinical Center, National Institutes of Health, MSC 1604, 10 Center Drive, Bethesda, MD, 20892, USA.
Galen O JoeRehabilitation Medicine Department, Clinical Center, National Institutes of Health, MSC 1604, 10 Center Drive, Bethesda, MD, 20892, USA.
Sandra A MitchellOutcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Susan BooherAutoimmunity and Mucosal Immunology Branch, Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Steven Z PavleticCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kristin BairdCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Edward W CowenDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Leora E ComisRehabilitation Medicine Department, Clinical Center, National Institutes of Health, MSC 1604, 10 Center Drive, Bethesda, MD, 20892, USA. comisl@cc.nih.gov.
National Institutes of Health Clinical Center · USNational Institutes of Health · USNational Cancer Institute · USNational Institute of Allergy and Infectious Diseases · US

Funding

NIH Chronic GVHD Study GroupZIABC011743 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLETIC, STEVEN · 2016 to 2025
$10.2M
Chronic graft-versus-host diseaseZIABC011549 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI COWEN, EDWARD · 2014 to 2021
$5.2M
Intramural NIH HHS ZIA BC011549Intramural NIH HHS ZIA BC011743
6 · The paper itself

Abstract

purposeTo explore improvement in motor ability, function, health-related quality of life (HRQOL), and symptom severity in patients with sclerotic chronic graft-versus-host disease (ScGVHD) in response to treatment as well as the relationship among changes on such measures.

methodsThis study was a secondary analysis of data from 13 individuals with severe ScGVHD enrolled in a clinical trial evaluating the efficacy of imatinib mesylate (clinicaltrials.gov identifier: NCT00702689). Self-reported, clinician-reported, and performance-based indicators of motor ability, function, HRQOL, and symptom severity were assessed at baseline and 6 months following the administration of imatinib mesylate.

resultsParticipants did not show statistically significant improvement on any measures over time. Approximately one-third of patients displayed clinically significant improvement on measures of motor ability (palmar pinch strength, dominant hand, 30.8%), functioning (Manual Ability Measure-36, 41.7%), HRQOL (Short Form 36 [SF-36] Mental Component Summary, 33.3%), and symptom severity (Lee Symptom Scale, 38.5%). Improvement in cGVHD symptom burden was correlated with improvement in function (Assessment of Motor and Process Skills [AMPS] and Disabilities of the Arm, Shoulder, and Hand [DASH] scores) and HRQOL (SF-36 Physical Component Summary scores).

conclusionsFindings suggest the potential utility of administering patient-reported and performance-based functional measures, such as the DASH and the AMPS, to patients with cGVHD. By understanding the functional consequences of ScGVHD, interdisciplinary teams of health care providers, including rehabilitation professionals, can work to improve long-term outcomes.

Indexed as

AdolescentAdultChildChronic DiseaseClinical Trials, Phase II as TopicFemaleGraft vs Host DiseaseHumansImatinib MesylateMaleMiddle AgedMotor SkillsQuality of LifeSclerosisYoung AdultImatinib MesylateAllogeneic hematopoietic stem cell transplantationChronic graft-versus-host diseaseFunctional impairmentHealth-related quality of lifeSclerosisSymptom burden

Identifiers

PMID31811481
PMCPMC8274957
OpenAlexW2993474789

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.